Tag: DEB

Cordis Launches SELUTION SLR™ PTA Drug-Eluting Balloon (DEB) in Japan

Peripheral/Endo by 0 comments

TOKYO–(BUSINESS WIRE)– #Cordis–Cordis, a global leader in interventional cardiovascular technologies, today announces the launch and availability of the SELUTION SLR™ PTA Drug-Eluting Balloon (DEB)1 for use in Japan. SELUTION SLR™ DEB is designed to deliver sirolimus in a controlled, sustained manner to reduce restenosis and restore vessel function. The SELUTION SFA Japan clinical trial results demonstrate durable clinical outcomes in a complex patient population, including 81.5% primary patency and 9

Continue Reading →

Cordis Unveiled Breakthrough Results from SELUTION DeNovo and SELUTION4ISR Randomized Trials at TCT 2025, Transforming Coronary Artery Disease (CAD) Treatment Beyond Stenting

Coronary/Structural Heart by 0 comments

SELUTION DeNovo Trial – the largest randomized Drug Eluting Balloon trial – demonstrates a SELUTION SLR™ DEB strategy is non-inferior to a Drug Eluting Stent treatment strategy in de novo lesions. SELUTION4ISR, a randomized controlled trial, proves SELUTION SLR™ DEB is an alternative to…

Continue Reading →

Cordis to Unveil 12-Month Results from Two SELUTION SLR™ DEB Randomized Clinical Trials at TCT 2025 Late-Breaking Clinical Trials Session

Coronary/Structural Heart by 0 comments

12-month data from pivotal randomized studies underscore Cordis’ commitment to shaping the future of cardiovascular care. MIAMI LAKES, Fla., Oct. 21, 2025 /PRNewswire/ — Cordis, a global leader in interventional cardiovascular technologies, will share late-breaking 12-month results from…

Continue Reading →